Tesla says that around 3 percent of Model Xs are likely to have the improperly tightened cable, but the electric auto firm wants to inspect all 11,000 vehicles built with that second-row setup. That's what Tesla issued today.
Tesla CEO Elon Musk demonstrates the falcon wing doors on the new Tesla Model X Crossover SUV during a launch event on September 29, 2015 in Fremont, California.Justin Sullivan/Getty ImagesTesla just issued a voluntary recall for 11,000 Model X SUVs because the seats could fail in the event of a crash. Vehicles with single-post seats are unaffected.
The California company says that the recall affects Model Xs fitted with a flat-folding second row that were built between October 26, 2016, and August 16, 2017. Improperly adjusted cables could cause the seat back on the driver-side second-row seat to move forward during a crash, which increases the chance of injury. There are no parts required for this inspection, and the adjustment will take only about 10 minutes to complete.
The letter has indicated that it is still "no issues" driving the Model X SUVs but customers' were told to avoid sitting in the second row left and centre seating positions at the same time until it has been ascertained that the issues to the cables are non-existent. It can be remedied at a Tesla service center or, if the owner wishes, through Tesla's mobile fix service. Child seats are still fine to use, as the LATCH system connects to the seat's base and not its back, and you can still put one adult or two children in those seats without concern.
Early voting begins for upcoming Nov.7 general election
New Yorkers can check the status of their voter registration and political party affiliation here or by calling 1-866-VOTE-NYC . Voters can also find information about the upcoming election and check their registration status on the site.
Ethics Committee extends review of Chris Collins
Collins told OCE he was "sure" he would have discussed Innate at the NIH meeting, but could not recall specific conversations. The company's prospects dropped after its multiple sclerosis drug failed to demonstrate a meaningful benefit for patients.